Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Legend Biotech (LEGN – Research Report), ACADIA Pharmaceuticals (ACAD – Research Report) and CytomX Therapeutics (CTMX – Research Report).
Legend Biotech (LEGN)
In a report released yesterday, Gena Wang from Barclays maintained a Buy rating on Legend Biotech, with a price target of $94.00. The company’s shares closed last Monday at $65.19.
According to TipRanks.com, Wang is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Legend Biotech with a $86.88 average price target, representing a 35.9% upside. In a report issued on February 26, H.C. Wainwright also reiterated a Buy rating on the stock with a $87.00 price target.
See today’s best-performing stocks on TipRanks >>
ACADIA Pharmaceuticals (ACAD)
ACADIA Pharmaceuticals received a Hold rating and a $25.00 price target from Mizuho Securities analyst Uy Ear yesterday. The company’s shares closed last Monday at $24.13.
According to TipRanks.com, Ear is a 4-star analyst with an average return of
Currently, the analyst consensus on ACADIA Pharmaceuticals is a Moderate Buy with an average price target of $33.71, implying a 44.7% upside from current levels. In a report issued on February 28, Stifel Nicolaus also maintained a Hold rating on the stock with a $26.00 price target.
CytomX Therapeutics (CTMX)
CytomX Therapeutics received a Buy rating and a $3.50 price target from Barclays analyst Peter Lawson yesterday. The company’s shares closed last Monday at $2.51.
According to TipRanks.com, Lawson is a 5-star analyst with an average return of
CytomX Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $2.75.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LEGN:
